onis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus (CHB). The results showed that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA for 24 weeks after end of bepirovirsen treatment in people with CHB. The study results were presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® in Washington, DC.
Anthony Scaramucci Wants You To Buy AI Stocks Even Though They Are ‘Probably In A Bubble’
Artificial intelligence (AI) stocks may be in a bubble, but they are still worth owning for long-term investors,…
